ANI Historical Income Statement

ANIP Stock

USD 61.66 0.25 0.40%

Historical analysis of ANI Pharmaceuticals income statement accounts such as Interest Expense of 18.5 M, Selling General Administrative of 262.1 M or Total Revenue of 645.1 M can show how well ANI Pharmaceuticals performed in making a profits. Evaluating ANI Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ANI Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ANI Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ANI Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Build AI portfolio with ANI Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

About ANI Income Statement Analysis

ANI Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ANI Pharmaceuticals shareholders. The income statement also shows ANI investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ANI Pharmaceuticals Income Statement Chart

At this time, ANI Pharmaceuticals' EBIT is relatively stable compared to the past year. As of 06/04/2025, Research Development is likely to grow to about 46.8 M, while Income Before Tax is likely to drop (23.3 M).

Total Revenue Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts ANI Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ANI Pharmaceuticals. It is also known as ANI Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from ANI Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' EBIT is relatively stable compared to the past year. As of 06/04/2025, Research Development is likely to grow to about 46.8 M, while Income Before Tax is likely to drop (23.3 M).

ANI Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Net Income From Continuing Ops	Non Operating Income Net Other	Discontinued Operations	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.86	0.88	0.93	0.92	0.93	0.1	0.18	0.6	0.74	0.92	-0.18	-0.31	0.93	0.31	-0.89	-0.04	0.24	-0.56	-0.27	-0.67	0.85	-0.64	0.92	0.55
Interest Expense	0.86		0.7	0.79	0.79	0.76	0.3	0.39	0.44	0.8	0.74	-0.04	-0.16	0.77	0.31	-0.83	0.09	0.35	-0.29	-0.21	-0.56	0.69	-0.84	0.79	0.28
Selling General Administrative	0.88	0.7		0.98	0.97	0.99	0.03	0.15	0.74	0.65	0.99	-0.19	-0.32	0.98	0.21	-0.85	-0.08	0.32	-0.82	-0.07	-0.55	0.74	-0.62	0.89	0.81
Total Revenue	0.93	0.79	0.98		1.0	0.99	0.19	0.29	0.7	0.77	0.98	-0.07	-0.21	0.99	0.27	-0.85	0.05	0.37	-0.75	-0.19	-0.5	0.79	-0.66	0.89	0.74
Gross Profit	0.92	0.79	0.97	1.0		0.98	0.24	0.35	0.69	0.8	0.97	0.0	-0.19	0.98	0.27	-0.84	0.1	0.4	-0.74	-0.21	-0.47	0.79	-0.66	0.88	0.73
Other Operating Expenses	0.93	0.76	0.99	0.99	0.98		0.06	0.17	0.75	0.69	1.0	-0.19	-0.28	0.99	0.2	-0.87	-0.07	0.32	-0.77	-0.15	-0.56	0.79	-0.65	0.91	0.76
Operating Income	0.1	0.3	0.03	0.19	0.24	0.06		0.97	-0.27	0.72	0.02	0.92	0.52	0.1	0.53	0.06	0.86	0.41	0.04	-0.38	0.4	0.15	-0.17	-0.03	-0.04
Ebit	0.18	0.39	0.15	0.29	0.35	0.17	0.97		-0.16	0.79	0.13	0.86	0.48	0.21	0.52	-0.04	0.81	0.56	-0.09	-0.43	0.35	0.2	-0.29	0.06	0.09
Research Development	0.6	0.44	0.74	0.7	0.69	0.75	-0.27	-0.16		0.26	0.78	-0.43	-0.18	0.7	-0.43	-0.62	-0.29	0.26	-0.64	-0.12	-0.34	0.54	-0.49	0.66	0.63
Ebitda	0.74	0.8	0.65	0.77	0.8	0.69	0.72	0.79	0.26		0.66	0.47	0.14	0.72	0.55	-0.58	0.53	0.53	-0.4	-0.46	-0.18	0.66	-0.59	0.6	0.4
Total Operating Expenses	0.92	0.74	0.99	0.98	0.97	1.0	0.02	0.13	0.78	0.66		-0.22	-0.31	0.99	0.16	-0.88	-0.09	0.32	-0.77	-0.14	-0.58	0.78	-0.64	0.91	0.76
Net Income	-0.18	-0.04	-0.19	-0.07	0.0	-0.19	0.92	0.86	-0.43	0.47	-0.22		0.42	-0.16	0.46	0.3	0.89	0.34	0.13	-0.28	0.5	-0.08	0.08	-0.25	-0.14
Income Tax Expense	-0.31	-0.16	-0.32	-0.21	-0.19	-0.28	0.52	0.48	-0.18	0.14	-0.31	0.42		-0.23	-0.06	0.51	0.38	0.19	0.13	-0.41	0.84	-0.19	0.29	-0.48	-0.13
Cost Of Revenue	0.93	0.77	0.98	0.99	0.98	0.99	0.1	0.21	0.7	0.72	0.99	-0.16	-0.23		0.26	-0.86	-0.04	0.31	-0.75	-0.16	-0.52	0.79	-0.65	0.89	0.75
Income Before Tax	0.31	0.31	0.21	0.27	0.27	0.2	0.53	0.52	-0.43	0.55	0.16	0.46	-0.06	0.26		-0.24	0.4	-0.08	-0.09	-0.14	-0.16	0.26	-0.15	0.22	0.09
Total Other Income Expense Net	-0.89	-0.83	-0.85	-0.85	-0.84	-0.87	0.06	-0.04	-0.62	-0.58	-0.88	0.3	0.51	-0.86	-0.24		0.19	-0.17	0.48	-0.04	0.77	-0.62	0.8	-0.94	-0.48
Net Income From Continuing Ops	-0.04	0.09	-0.08	0.05	0.1	-0.07	0.86	0.81	-0.29	0.53	-0.09	0.89	0.38	-0.04	0.4	0.19		0.27	0.08	-0.33	0.39	0.04	0.04	-0.16	-0.08
Non Operating Income Net Other	0.24	0.35	0.32	0.37	0.4	0.32	0.41	0.56	0.26	0.53	0.32	0.34	0.19	0.31	-0.08	-0.17	0.27		-0.29	-0.38	0.13	0.17	-0.38	0.23	0.29
Discontinued Operations	-0.56	-0.29	-0.82	-0.75	-0.74	-0.77	0.04	-0.09	-0.64	-0.4	-0.77	0.13	0.13	-0.75	-0.09	0.48	0.08	-0.29		0.08	0.22	-0.47	0.23	-0.48	-0.8
Non Recurring	-0.27	-0.21	-0.07	-0.19	-0.21	-0.15	-0.38	-0.43	-0.12	-0.46	-0.14	-0.28	-0.41	-0.16	-0.14	-0.04	-0.33	-0.38	0.08		-0.22	-0.44	-0.02	-0.06	-0.03
Tax Provision	-0.67	-0.56	-0.55	-0.5	-0.47	-0.56	0.4	0.35	-0.34	-0.18	-0.58	0.5	0.84	-0.52	-0.16	0.77	0.39	0.13	0.22	-0.22		-0.51	0.49	-0.74	-0.23
Interest Income	0.85	0.69	0.74	0.79	0.79	0.79	0.15	0.2	0.54	0.66	0.78	-0.08	-0.19	0.79	0.26	-0.62	0.04	0.17	-0.47	-0.44	-0.51		-0.45	0.77	0.58
Net Interest Income	-0.64	-0.84	-0.62	-0.66	-0.66	-0.65	-0.17	-0.29	-0.49	-0.59	-0.64	0.08	0.29	-0.65	-0.15	0.8	0.04	-0.38	0.23	-0.02	0.49	-0.45		-0.73	-0.21
Reconciled Depreciation	0.92	0.79	0.89	0.89	0.88	0.91	-0.03	0.06	0.66	0.6	0.91	-0.25	-0.48	0.89	0.22	-0.94	-0.16	0.23	-0.48	-0.06	-0.74	0.77	-0.73		0.61
Extraordinary Items	0.55	0.28	0.81	0.74	0.73	0.76	-0.04	0.09	0.63	0.4	0.76	-0.14	-0.13	0.75	0.09	-0.48	-0.08	0.29	-0.8	-0.03	-0.23	0.58	-0.21	0.61

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	44.6M	47.3M	57.0M	59.8M	67.7M	71.1M
Interest Expense	9.5M	11.9M	28.1M	26.9M	17.6M	18.5M
Selling General Administrative	65.0M	84.3M	127.8M	150.4M	249.6M	262.1M
Total Revenue	208.5M	216.1M	316.4M	486.8M	614.4M	645.1M
Gross Profit	121.3M	115.5M	177.6M	305.3M	364.2M	382.4M
Other Operating Expenses	224.0M	244.3M	342.1M	439.8M	613.8M	644.5M
Operating Income	(16.1M)	(32.5M)	(25.1M)	47.0M	584K	613.2K
Ebit	(15.6M)	(48.9M)	(8.9M)	46.8M	11.4M	12.0M
Research Development	16.0M	11.4M	22.3M	34.3M	44.6M	46.8M
Ebitda	29.1M	(1.7M)	48.1M	106.6M	79.1M	83.1M
Total Operating Expenses	136.9M	143.7M	203.3M	258.3M	363.6M	381.8M
Net Income	(22.5M)	(42.6M)	(47.9M)	18.8M	(18.5M)	(17.6M)
Income Tax Expense	(3.4M)	(13.5M)	(14.8M)	1.1M	(3.7M)	(3.9M)
Cost Of Revenue	87.2M	100.6M	138.8M	181.5M	250.2M	262.7M
Income Before Tax	(26.0M)	(56.1M)	(62.7M)	19.9M	(22.2M)	(23.3M)
Total Other Income Expense Net	(9.9M)	(16.3M)	(27.4M)	(27.1M)	(22.8M)	(23.9M)
Net Income From Continuing Ops	(22.5M)	(42.6M)	(47.9M)	13.4M	(18.5M)	(17.6M)
Non Operating Income Net Other	(228K)	(494K)	(4.3M)	670K	770.5K	809.0K
Net Income Applicable To Common Shares	6.1M	(22.5M)	(42.8M)	(49.5M)	(44.6M)	(42.3M)
Tax Provision	(3.4M)	(13.5M)	(14.8M)	(184K)	(3.7M)	(3.5M)
Net Interest Income	(9.5M)	(11.9M)	(28.1M)	(28.7M)	(17.6M)	(18.5M)
Reconciled Depreciation	44.6M	47.3M	57.0M	60.2M	67.7M	52.7M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

ANI Historical Income Statement

About ANI Income Statement Analysis

ANI Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

ANI Pharmaceuticals income statement Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals income statement Accounts

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Other Operating Expenses	+ 0.99	Selling General Administrative
Total Operating Expenses	+ 0.99	Selling General Administrative
Other Operating Expenses	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Total Revenue

Reconciled Depreciation	- 0.94	Total Other Income Expense Net
Total Other Income Expense Net	- 0.89	Depreciation And Amortization
Total Other Income Expense Net	- 0.88	Total Operating Expenses
Total Other Income Expense Net	- 0.87	Other Operating Expenses
Total Other Income Expense Net	- 0.86	Cost Of Revenue
Total Other Income Expense Net	- 0.85	Total Revenue